Key Takeaways
- • The Nuclear Energy Agency (NEA), US Department of Energy (DOE), and European Commission's Joint Research Centre (JRC) co-organized the Second International Workshop on Medical Radioisotopes Supply to establish secure supply chains for cancer diagnostic and therapeutic radioisotopes.
- • Global cancer burden is projected to surge from 10 million deaths in 2020 to 16.3 million deaths by 2040, creating urgent demand for advanced nuclear medical technologies including radioligand therapy (RLT) and novel radioisotopes.
- • The workshop prioritized critical supply chain challenges for Lutetium-177 (177Lu) and Actinium-225 (225Ac)—emerging therapeutic radioisotopes—alongside infrastructure resilience and supply-demand monitoring across medical systems.
- • The second workshop expanded on the first edition, which convened over 270 experts in-person and online, reflecting sustained international commitment to solving medical radioisotope supply constraints that affect cancer treatment capacity.
- • The event brought together governmental decision makers, private sector representatives, health organizations, and researchers to identify infrastructure gaps and coordinate development of resilient nuclear medicine supply ecosystems.
Summary
The Second International Workshop on Medical Radioisotopes Supply, co-organized by the OECD Nuclear Energy Agency, the US Department of Energy, and the European Commission's Joint Research Centre, addressed critical infrastructure and supply chain challenges in nuclear medicine as cancer incidence accelerates globally. The workshop convened governmental officials, industry representatives, healthcare organizations, and researchers to develop coordinated strategies for securing reliable supplies of radioisotopes used in cancer diagnostics and treatment.
The urgency driving the initiative reflects stark epidemiological trends. Cancer claimed nearly 10 million lives in OECD member countries during 2020, with one in five people at risk of developing the disease over their lifetime. Projections indicate the burden will intensify substantially—cancer cases are expected to reach 27.5 million annually by 2040, with corresponding deaths reaching 16.3 million, driven primarily by population growth and aging. Current therapeutic approaches including surgery, chemotherapy, and immunotherapy continue advancing, but emerging radioligand therapy technologies and novel radioisotopes represent a frontier expansion in cancer treatment capacity.
The workshop built momentum from its predecessor, which assembled over 270 experts across in-person and virtual participation. The second edition narrowed focus on high-priority supply chain vulnerabilities, particularly surrounding Lutetium-177 and Actinium-225—innovative therapeutic radioisotopes with expanding clinical applications. Key discussion topics included supply and demand forecasting mechanisms, critical infrastructure requirements for medical systems, and strategies to strengthen supply chain resilience across geographies. These discussions underscore that reliable radioisotope availability is not merely a pharmaceutical logistics issue but a healthcare system capacity constraint affecting cancer treatment outcomes.
The convening reflects a consensus among stakeholder communities that fragmented, under-monitored supply chains pose systemic risks as global demand for nuclear medicine accelerates. By bringing together regulators, commercial entities, and medical institutions under coordinated multilateral frameworks, the workshop positions nuclear medicine supply development as a strategic priority requiring sustained international coordination and infrastructure investment.
The urgency driving the initiative reflects stark epidemiological trends. Cancer claimed nearly 10 million lives in OECD member countries during 2020, with one in five people at risk of developing the disease over their lifetime. Projections indicate the burden will intensify substantially—cancer cases are expected to reach 27.5 million annually by 2040, with corresponding deaths reaching 16.3 million, driven primarily by population growth and aging. Current therapeutic approaches including surgery, chemotherapy, and immunotherapy continue advancing, but emerging radioligand therapy technologies and novel radioisotopes represent a frontier expansion in cancer treatment capacity.
The workshop built momentum from its predecessor, which assembled over 270 experts across in-person and virtual participation. The second edition narrowed focus on high-priority supply chain vulnerabilities, particularly surrounding Lutetium-177 and Actinium-225—innovative therapeutic radioisotopes with expanding clinical applications. Key discussion topics included supply and demand forecasting mechanisms, critical infrastructure requirements for medical systems, and strategies to strengthen supply chain resilience across geographies. These discussions underscore that reliable radioisotope availability is not merely a pharmaceutical logistics issue but a healthcare system capacity constraint affecting cancer treatment outcomes.
The convening reflects a consensus among stakeholder communities that fragmented, under-monitored supply chains pose systemic risks as global demand for nuclear medicine accelerates. By bringing together regulators, commercial entities, and medical institutions under coordinated multilateral frameworks, the workshop positions nuclear medicine supply development as a strategic priority requiring sustained international coordination and infrastructure investment.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.